Eledon Pharmaceuticals, Inc. (ELDN) stock
ELDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.98+0.01 (+0.51%)
Close on Nov 17, 2026Market cap $160.90MP/E –Yield –
Eledon Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Eledon Pharmaceuticals's operating income for the twelve months ending Sep 30, 2024 was -$56.22M. For fiscal 2023 it was -$43.00M. The highest annual figure on record is -$5.13M in fiscal 2016.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$43.00M | – |
| FY2022 | Dec 31, 2022 | -$88.43M | – |
| FY2021 | Dec 31, 2021 | -$36.87M | – |
| FY2020 | Dec 31, 2020 | -$18.47M | – |
| FY2019 | Dec 31, 2019 | -$16.05M | – |
| FY2018 | Dec 31, 2018 | -$14.06M | – |
| FY2017 | Dec 31, 2017 | -$13.12M | – |
| FY2016 | Dec 31, 2016 | -$5.13M | – |
| FY2015 | Dec 31, 2015 | -$45.26M | – |
| FY2014 | Dec 31, 2014 | -$23.46M | – |
| FY2013 | Dec 31, 2013 | -$15.75M | – |
| FY2012 | Dec 31, 2012 | -$9.65M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$22.87M | – |
| Q1 FY2026 | Mar 31, 2026 | -$21.18M | – |
| Q3 FY2025 | Sep 30, 2025 | -$19.07M | – |
| Q2 FY2025 | Jun 30, 2025 | -$24.73M | – |
| Q1 FY2025 | Mar 31, 2025 | -$17.96M | – |
| Q3 FY2024 | Sep 30, 2024 | -$20.51M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.50M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.87M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.34M | – |
| Q3 FY2023 | Sep 30, 2023 | -$11.20M | – |
| Q2 FY2023 | Jun 30, 2023 | -$10.35M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.11M | – |
| Q4 FY2022 | Dec 31, 2022 | -$58.69M | – |
| Q3 FY2022 | Sep 30, 2022 | -$10.60M | – |
| Q2 FY2022 | Jun 30, 2022 | -$9.28M | – |
| Q1 FY2022 | Mar 31, 2022 | -$9.86M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.39M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.51M | – |
| Q2 FY2021 | Jun 30, 2021 | -$7.97M | – |
| Q1 FY2021 | Mar 31, 2021 | -$9.01M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.35M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.15M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.59M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.38M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.17M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.92M | – |
| Q2 FY2019 | Jun 30, 2019 | -$4.09M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.88M | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.58M | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.50M | – |
| Q2 FY2018 | Jun 30, 2018 | -$3.19M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.80M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.11M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.97M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.67M | – |
| Q1 FY2017 | Mar 31, 2017 | -$1.39M | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.76M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.62M | – |
See a number that looks wrong?